PCRX Q1 2019 Earnings — Pacira BioSciences, Inc. Revenue & Financial Results | Market Cap Arena

PCRXPacira BioSciences, Inc.

$969M

Q1 2019 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$91M+22.4% YoY

Gross Profit

$64M70.1% margin

Operating Income

$1M1.2% margin

Net Income

-$3M-3.0% margin

EPS (Diluted)

$-0.07

QoQ Revenue Growth

-4.0%

Cash Flow

Operating Cash Flow

$3M

Free Cash Flow

$1M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$719M

Total Liabilities

$392M

Stockholders' Equity

$328M

Cash & Equivalents

$215M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$91M	$75M	+22.4%
Gross Profit	$64M	$52M	+23.8%
Operating Income	$1M	-$7M	+115.6%
Net Income	-$3M	-$11M	+74.1%

Revenue Segments

EXPAREL

$91M100%

DepoCyt(e) and Other Products

$291,0000%